On May 20, 2019, the PTAB denied a request for rehearing in Apotex Inc. v. Amgen Inc., Case IPR2016-01542 (Paper 67), but modified its...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
Apotex
-
-
Recently, in Adello Biologics LLC v. Amgen Inc., Case PGR2019-00001 (Paper No. 13) (PTAB Apr. 19, 2019), the PTAB instituted...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Earlier this month, Amgen initiated suit against Apotex in the Middle District of Florida, alleging infringement of U.S. Patent No....
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Biologic drugs are large molecules, such as therapeutic proteins, DNA vaccines, monoclonal antibodies, and fusion proteins, that are...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Several of the Federal Circuit’s initial decisions involving the Biologics Price Competition and Innovation Act (the “BPCIA”) focused...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Introduction and Background The Apotex filgrastim/pegfilgrastim biosimilar litigation was the first biosimilar litigation where the...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]